Achilles Therapeutics

Achilles Therapeutics: Developing precision TIL-based therapy called cNeT - clonal neoantigen targeting T cells – with the goal of targeting the most specific tumor antigens. Patients dosed in P I/II CHIRON (NSCLC) and THETIS (Melanoma) studies evaluating safety, tolerability and clinical activity of cNeT.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Phase l or ll, Pre-Clinical Stage
Disease Space
Immuno-Oncology, Immunotherapy, Oncology
Industry
Biotechnology, Life Sciences
Listing
Private
Website:
Address:
245 Hammersmith Road
London, W6 8PW
United Kingdom

Company Participants at Solebury Trout Management Access SF 2020

  • Beverley Carr, PhD, Chief Business Officer
  • Edwin Moses, PhD, Chairman of the Board
  • Iraj Ali, PhD, CEO
  • Michael Giordano, Director